Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Keros Therapeutics, Inc. (NASDAQ:KROS) has received a consensus recommendation of “Moderate Buy” from the fourteen ratings firms that are presently covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $42.33.

Several analysts recently weighed in on the stock. Piper Sandler cut their price target on shares of Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating on the stock in a report on Friday, January 17th. TD Cowen lowered shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. William Blair downgraded Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, December 12th. Cantor Fitzgerald cut Keros Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Tuesday, January 21st. Finally, Scotiabank reduced their price target on Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating on the stock in a research note on Thursday, January 16th.

Institutional Trading of Keros Therapeutics

Institutional investors have recently bought and sold shares of the company. AlphaQuest LLC raised its holdings in Keros Therapeutics by 469.0% in the fourth quarter. AlphaQuest LLC now owns 3,596 shares of the company’s stock worth $57,000 after buying an additional 2,964 shares during the last quarter. Victory Capital Management Inc. bought a new stake in shares of Keros Therapeutics during the third quarter valued at approximately $216,000. Point72 Asia Singapore Pte. Ltd. raised its holdings in Keros Therapeutics by 36.7% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,844 shares of the company’s stock worth $223,000 after acquiring an additional 1,033 shares during the last quarter. Virtus ETF Advisers LLC raised its holdings in Keros Therapeutics by 107.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 3,857 shares of the company’s stock worth $61,000 after acquiring an additional 1,998 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Keros Therapeutics by 59.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,371 shares of the company’s stock valued at $312,000 after acquiring an additional 1,994 shares in the last quarter. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Price Performance

NASDAQ KROS opened at $10.99 on Friday. Keros Therapeutics has a 1 year low of $9.78 and a 1 year high of $72.37. The stock has a market capitalization of $445.78 million, a PE ratio of -2.11 and a beta of 1.39. The business’s 50-day moving average is $11.15 and its 200 day moving average is $34.88.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.36) by $0.22. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm had revenue of $3.04 million for the quarter, compared to analyst estimates of $37.32 million. As a group, equities research analysts anticipate that Keros Therapeutics will post -4.74 earnings per share for the current year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.